Hendra Virus Vaccine, a One Health Approach to Protecting Horse, Human, and Environmental Health
Deborah Middleton1 , Jackie Pallister1, Reuben Klein, Yan-Ru Feng, Jessica Haining, Rachel Arkinstall, Leah Frazer, Jin-An Huang, Nigel Edwards, Mark Wareing, Martin Elhay, Zia Hashmi, John Bingham, Manabu Yamada, Dayna Johnson, John White, Adam Foord, Hans G. Heine, Glenn A. Marsh, Christopher C. Broder, and Lin-Fa Wang
Author affiliations: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia (D. Middleton, J. Pallister, R. Klein, J. Haining, R. Arkinstall, L. Frazer, J. Bingham, D. Johnson, J. White, A. Foord, H.G. Heine, G.A. Marsh, L.-F. Wang); Uniformed Services University, Bethesda, Maryland, USA (Y.-R. Feng, C.C. Broder); Zoetis Research & Manufacturing Pty Ltd, Parkville, Victoria, Australia (J.-A. Huang, N. Edwards, M. Wareing, M. Elhay, Z. Hashmi); National Institute of Animal Health, Ibaraki, Japan (M. Yamada); Duke–NUS (Duke and the National University of Singapore) Graduate Medical School, Singapore (L.-F. Wang)
Figure 1. Histologic and immunohistologic findings in Hendra virus–infected horse tissueA) Hematoxylin and eosin staining shows systemic vasculitis affecting the lungB) Immunohistologic examination, using polyclonal rabbit anti-Nipah N protein, indicates Hendra virus antigen in a blood vessel in the brainScale bars represent 50 μm.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.